Archive for March, 2013

Upcoming Webinar: Finding Your Strongest Voice for Public Testimony

March 27, 2013

The upcoming FDA Workshop on Drug Development is a historic opportunity for the ME/CFS* community to establish ME/CFS as a priority for drug development. Learn more about the FDA workshop here: http://bit.ly/fda-mtg-agenda To inform, educate and engage with the community so that our individual contributions have […]

FDA Workshop Agenda & Details Announced

March 21, 2013

The U.S. Food and Drug Administration (FDA) will host a workshop on drug development and CFS and ME on April 25-26, 2013. This FDA workshop will also serve as the first of 20 disease-specific meetings where the FDA will gather patients’ perspectives as part of […]

T & NK CELL SUBSET DIFFERENCES:

March 20, 2013

Researchers in Spain studied fresh blood samples collected from 22 CFS patients (94-Fukuda criteria) who did not have concurrent evidence of infections and compared function of several immune cell subsets to 30 healthy controls. They found differences in T cells and natural killer (NK) cell […]

GULF WAR BRAIN BIOMARKER

March 20, 2013

Dr. James Baraniuk and Georgetown Univ. colleagues studied 31 chronically ill Gulf War veterans and 20 sedentary, healthy controls using functional MRI testing. Gulf War Illness subjects had significantly correlated fatigue, pain, hyperalgesia and increased axial diffusivity in the right inferior fronto-occipital fasciculus area of […]

CFS & ME Compared

March 20, 2013

Using 3 independent data sets (including the SolveCFS BioBank), Dr. Leonard Jason and colleagues found that fewer subjects met criteria for ME than CFS and symptoms were more severe and impairments were greater for subjects who met ME criteria. (Fatigue: Biomedicine, Health & Behavior, Mar. […]

HEART RATE VARIABILITY DURING SLEEP

March 18, 2013

This study by Drs. Benjamin Natelson and Fumharu Togo looked for a relationship between heart rate variability (HRV) and subjective sleep quality. The 52 female patients with CFS showed evidence for sleep disruption in the form of significantly reduced total sleep time, reduced sleep efficiency, […]

Upcoming Webinar: Overview of the Drug Development Landscape

March 18, 2013

The upcoming FDA Workshop on Drug Development is a historic opportunity for the ME/CFS* community to establish ME/CFS as a priority for drug development. To inform, educate and engage with the community so that our individual contributions have amplified impact, we are pleased to announce a […]

Catalyzing Informed Action: Webinar Series & Patient Survey

March 18, 2013

The U.S. Food and Drug Administration (FDA) will host a workshop on drug development and CFS and ME on April 25-26, 2013. This FDA workshop will also serve as the first of 20 disease-specific meetings where the FDA will gather patients’ perspectives as part of […]

ABNORMAL PAIN PROCESSING

March 13, 2013

19 patients with CFS/FM, 16 patients with rheumatoid arthritis (RA) and 18 sedentary controls participated in a double-blind crossover trial of a single dose (1 g) of acetaminophen with tests of pressure pain threshold before and after treatment. The group of Belgian researchers led by […]

New $2 Million CFS Grant Awarded to Dr. Dikoma Shungu & Team

March 7, 2013

The following press release issued today announces a new $2 million research grant to a team led by Dr. Dikoma Shungu of Weill Cornell Medical College. The award from the National Institutes of Health was made based on pilot data Dr. Shungu’s team collected with support from two pilot […]